Inhibition of IFN-gamma signaling by glucocorticoids

J Immunol. 2003 May 1;170(9):4833-9. doi: 10.4049/jimmunol.170.9.4833.

Abstract

Recent reports suggest that a novel mechanism of glucocorticoid (GC) immunosuppressive action is inhibition of signaling by IL-2 and IL-12, cytokines that use the Janus kinase-STAT signaling pathway. We investigated whether GCs could also block activation of Janus kinase-STAT signaling by IFN-gamma, a potent proinflammatory cytokine. Addition of dexamethasone to PBMC cultures resulted in a dramatic inhibition of IFN-gamma activation of STAT1. Several days of exposure to GCs were required for inhibition of IFN-gamma signaling to become apparent, and the underlying mechanism was down-regulation of STAT1 expression. GCs suppressed the expression of STAT1 mRNA, but did not affect STAT1 protein stability. STAT1 expression and IFN-gamma signaling were preferentially suppressed in macrophages. GCs did not act directly on macrophages, but worked indirectly by regulating macrophage-lymphocyte interactions that control STAT1 expression. GCs inhibited IFN-gamma-inducible gene expression, thus demonstrating the physiological significance of inhibition of signal transduction. Our results identify a novel level of regulation of IFN-gamma signaling, whereby GCs control the amplitude of IFN-gamma signaling by regulating STAT1 expression. These results suggest that inhibition of IFN-gamma signaling contributes to the immunosuppressive action of GCs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Inflammatory Agents / pharmacology
  • Cells, Cultured
  • Chemokine CXCL10
  • Chemokines, CXC / antagonists & inhibitors
  • Chemokines, CXC / biosynthesis
  • Chemokines, CXC / genetics
  • DNA-Binding Proteins / antagonists & inhibitors
  • DNA-Binding Proteins / biosynthesis
  • DNA-Binding Proteins / genetics
  • Dexamethasone / pharmacology*
  • Down-Regulation / drug effects*
  • Down-Regulation / immunology*
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / immunology
  • Humans
  • Immunosuppressive Agents / pharmacology*
  • Interferon Regulatory Factor-1
  • Interferon-gamma / antagonists & inhibitors*
  • Interferon-gamma / genetics
  • Interferon-gamma / metabolism
  • Interferon-gamma / physiology*
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Lipopolysaccharide Receptors / biosynthesis
  • Lipopolysaccharide Receptors / blood
  • Milk Proteins*
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / metabolism
  • Phosphoproteins / antagonists & inhibitors
  • Phosphoproteins / biosynthesis
  • Phosphoproteins / genetics
  • RNA, Messenger / antagonists & inhibitors
  • RNA, Messenger / biosynthesis
  • STAT1 Transcription Factor
  • STAT5 Transcription Factor
  • Signal Transduction / drug effects*
  • Signal Transduction / immunology*
  • Time Factors
  • Trans-Activators / antagonists & inhibitors
  • Trans-Activators / biosynthesis
  • Trans-Activators / genetics

Substances

  • Anti-Inflammatory Agents
  • Chemokine CXCL10
  • Chemokines, CXC
  • DNA-Binding Proteins
  • IRF1 protein, human
  • Immunosuppressive Agents
  • Interferon Regulatory Factor-1
  • Lipopolysaccharide Receptors
  • Milk Proteins
  • Phosphoproteins
  • RNA, Messenger
  • STAT1 Transcription Factor
  • STAT1 protein, human
  • STAT5 Transcription Factor
  • Trans-Activators
  • Dexamethasone
  • Interferon-gamma